GETI Gentek, Inc. (MM)

MVC Capital, Inc. (NYSE: MVC) (�MVC�), a publicly traded business development company that makes private debt and equity investments, today announced that it has made a follow-on investment in Summit Research Labs, Inc. (�Summit�), an existing portfolio company of the Fund, in order to support Summit�s acquisition of Reheis, Inc. (�Reheis�). Reheis, a subsidiary of GenTek Inc. (NASDAQ: GETI), is a leading producer of aluminum- and zirconium-based chemicals, the active ingredients in antiperspirants. Summit believes that the transaction will create the global market leader in antiperspirant actives manufacturing, and will enable it to achieve increased economies of scale and other operational efficiencies, as well as an established international sales and distribution network. Reheis� vaccine adjuvant and potassium chloride businesses will remain with GenTek. After the acquisition, Summit will do business as SummitReheis, and Piyush Patel, Summit�s Chief Executive Officer, will continue to serve as the CEO. MVC will remain the majority shareholder of Summit. In addition to its investment, MVC arranged for a new credit facility for Summit to create a capital structure to allow for appropriate liquidity and growth. �We are delighted to be able to support Summit�s continued growth and product expansion,� said Michael Tokarz, Chairman and Portfolio Manager of MVC. �The combination of Summit and Reheis will create a stronger entity that will be better positioned to compete internationally in the antiperspirant and deodorant industry. We are confident that Summit has the right leadership team in place to maximize the combined company's opportunities.� �Summit provides an attractive growth platform that is consistent with MVC�s strategy in the specialty chemical industry. This acquisition will potentially result in cost savings, strengthen Summit�s sales and distribution foothold in Europe and Latin America and foster new product development activity for Summit�s customers,� said Shivani Khurana, Vice President of MVC Financial Services, Inc. Piyush Patel, CEO of Summit, said, �We are grateful for MVC�s continued financial and operational support as we work to enhance our market position, both through internal growth and strategic acquisitions. SummitReheis merges the strengths of two established organizations and allows us to offer optimal sales coverage, research & development, technical service, and manufacturing and distribution efficiencies to our customers. The knowledge base that results by combining the technical organizations of the antiperspirant businesses is unparalleled.� MVC-G About MVC Capital, Inc. MVC is a business development company traded on the New York Stock Exchange that provides long-term debt and equity investment capital to fund growth, acquisitions and recapitalizations of companies in a variety of industries. For additional information about MVC, please visit the MVC's website at www.mvccapital.com. All media inquiries should be directed to Nathaniel Garnick at 212-687-8080. About Summit Research Labs, Inc. Based in Huguenot, New York, Summit is a specialty chemical company that manufactures antiperspirant actives -- chemical ingredients that give antiperspirants their sweat-blocking ability. Summit has expertise in particle size reduction and spray drying, and is a high quality global supplier to large consumer products and personal care products companies. To learn more about Summit, visit its website at www.summitresearchlabs.com The information contained in this press release contains forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. Certain factors could cause actual results and conditions to differ materially from those projected in these forward-looking statements, and these factors are enumerated in the company's periodic filings with the Securities and Exchange Commission.